The Fundamental Case for and Against Boston Scientific Corporation (BSX)

Boston Scientific Corporation (NYSE:BSX) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market value of 51.95B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Boston Scientific Corporation (NYSE:BSX) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For BSX, the company currently has 168 million of cash on the books, which is offset by 453 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 0 in total assets, balanced by 16 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Boston Scientific Corporation saw 0 in free cash flow last quarter, representing a quarterly net change in cash of 81 million. Perhaps most importantly where cash movements are concerned, the company saw about 0 in net operating cash flow.

Boston Scientific Corporation (NYSE:BSX) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 2.39 billion in total revenues. That represents a quarterly year/year change in revenues of 0.07% in sequential terms, the BSX saw sales decline by -0.04%.

But what about the bottom line? After all, that’s what really matters in the end. Boston Scientific Corporation is intriguing when broken down to its core data. The cost of selling goods last quarter was 672 million, yielding a gross basic income of 1.72 billion. For shareholders, given the total diluted outstanding shares of 1.40B, this means overall earnings per share of 310. Note, this compares with a consensus analyst forecast of 0.37 in earnings per share for its next fiscal quarterly report.

Is Boston Scientific Corporation (NYSE:BSX) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 1.58 in total earnings per share. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Boston Scientific Corporation.

Previous ArticleNext Article

Related Post

Exact Sciences Corporation (EXAS): More In-Depth M... Exact Sciences Corporation (NASDAQ:EXAS) has recently been identified as an interesting stock but more in-depth monitoring is needed for a trade decis...
Fundamentals in Focus for Comstock Mining Inc. (LO... It is interesting to note that Comstock Mining Inc. (NYSE:LODE) is active and made a solid movement in the last trading day. Now trading with a market...
The Fundamental Facts on IAMGOLD Corporation (IAG) It's worth it to have a look at IAMGOLD Corporation (NYSE:IAG) as there may be a chasm between the bulls and the bears as far as recent trading activi...
Yandex N.V. (YNDX): Does This Move Make Any Sense ... Yandex N.V. (NASDAQ:YNDX) is an interesting stock at present. Now trading with a market value of 9.80B, the company has a mix of catalysts and obstacl...
Amarin Corporation plc (AMRN) Raising Eyebrows Amo... Amarin Corporation plc (NASDAQ:AMRN) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market v...